The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030.

Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access

Roots Analysis is pleased to announce the publication of its recent study, titled, “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed review of the overall landscape of the non-invasive cancer diagnostics market. 

§  An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019.

§  An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics.

§  An analysis of the initiatives of big pharma players.

§  A detailed acquisition target analysis.

§  Elaborate profiles of the key players engaged in this domain.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

• Type of Tumor Marker

• ctDNA
• cfDNA
• CTCs
• Exosomes
• Others

• Application

• Diagnosis / Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

• Target Cancer Indication

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Gastric Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

To request for sample report - https://www.rootsanalysis.com/reports/279/request-sample.html

§  End Users

• Hospitals
• Research Institutes
• Others

§  Key Geographical Regions 

• North America
• Europe

§  Asia-Pacific

§  Rest of the World

Key companies covered in the report:

§  Amoy Diagnostics

§  DiaCarta

§  HaploX Biotechnology

§  NeoGenomics

§  QIAGEN

§  Swift Biosciences

§  Sysmex Inostics

§  Thermo Fisher Scientific

For more information, please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

Other recent offerings

1. DNA-Encoded Libraries: Platforms and Services Market
2. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
3. In Silico / Computer-Aided Drug Discovery Services
4. Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Article source: https://article-realm.com/article/Sports-Recreation/15067-The-non-invasive-cancer-diagnostics-market-is-estimated-to-be-worth-around-USD-20-1-billion-by-2030.html